Nisha Jhalani
Cardiovascular Disease · New York, NYNPI 1265674618
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $387,785 of the $443,445 with a category attached, or 87.4%. 23 manufacturers reported payments, led by Novo Nordisk at 39.6% of the total. Reporting peaked in 2022 at $108,784 and has fallen 60.6% since, to $42,894 in 2025. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 570 payments — averaging $777.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$176K
- Boehringer Ingelheim$98K
- AstraZeneca$70K
- Lilly USA, LLC$63K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$26K
- Regeneron$6K
- plus $6K from 17 others
What the payments were for
- Consulting fees$12,9303%
- Speaking & faculty fees$387,78587%
- Travel & lodging$28,2376%
- Food & beverage$14,4293%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 97 | $175,615 |
| Boehringer Ingelheim | 122 | $98,069 |
| AstraZeneca | 92 | $70,075 |
| Lilly USA, LLC | 143 | $62,794 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 42 | $25,540 |
| Regeneron | 10 | $5,643 |
| Heartflow, Inc. | 5 | $2,072 |
| Astrazeneca UK Limited | 1 | $1,375 |
| Medtronic | 3 | $372 |
| Novartis | 12 | $354 |
| Johnson & Johnson | 15 | $291 |
| Amgen | 12 | $256 |
| Cleerly, Inc. | 4 | $234 |
| Irhythm Technologies, Inc. | 1 | $175 |
| Philips North America LLC | 2 | $147 |
| Edwards Lifesciences | 1 | $128 |
| Cardiovascular Systems Inc. | 1 | $111 |
| E.r. Squibb & Sons, L.L.C. | 2 | $61 |
| Biobeat USA Inc. | 1 | $39 |
| Abbott | 1 | $27 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $24 |
| Boston Scientific | 1 | $22 |
| Lantheus Medical Imaging, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$158,835
- Ozempic$97,173
- FARXIGA$70,322
- LifeVest$24,723
- RYBELSUS$15,267
- PRALUENT$5,485
- FFRct$2,000
- ONYX FRONTIER$335
- ZIO Patch$175
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$128
- (6346) Intrasight Mobile$115
- (6585) Omniwire$115
- (6571) Eagle Eye$115
- Coronary Orbital Atherectomy System$111
- LEQVIO$101
How this compares
$443,445 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 58 | $50,380 |
| XareltoRivaroxaban | 17 | $16,554 |
| JardianceEmpagliflozin | 24 | $14,571 |
| OzempicSemaglutide | 12 | $11,128 |
| EntrestoSacubitril/Valsartan | 11 | $8,652 |
| Metoprolol Succinate | 46 | $875 |
| Atorvastatin Calcium | 66 | $835 |
| SynthroidLevothyroxine Sodium | 16 | $759 |
| Rosuvastatin Calcium | 77 | $710 |
| Amlodipine Besylate | 45 | $678 |
| ValacyclovirValacyclovir Hcl | 15 | $629 |
| Losartan Potassium | 50 | $627 |
| Hydrochlorothiazide | 22 | $300 |
| Zolpidem Tartrate | 32 | $193 |
| Clonazepam | 13 | $153 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $291 | $16,55417 claims |
| Boehringer IngelheimJardiance | $98,069 | $14,57124 claims |
| Novo NordiskOzempic | $175,615 | $11,12812 claims |
| NovartisEntresto | $354 | $8,65211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in New York
- Roger HajjarNew York$5.2M
- Gregg StoneNew York$2M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Megha PrasadNew York$813K
- Eyal HerzogNew York$645K
- Roxana MehranNew York$432K
- Howard WeintraubNew York$328K
- Anuradha Lala-TrindadeNew York$324K
- Steven MarxNew York$323K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.